Clinical Trial Update: Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating adoptive immunotherapy with haploidentical Kir ligand-mismatched natural killer cells in high-risk acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Haploidentical Kir ligand-mismatched Natural Killer Cells

Snippet

Sponsor: University of Bologna | Conditions: Myeloblastic Leukemia | Phase 1 | Status: UNKNOWN